203 related articles for article (PubMed ID: 26329904)
1. The function and mechanisms of action of LOXL2 in cancer (Review).
Wu L; Zhu Y
Int J Mol Med; 2015 Nov; 36(5):1200-4. PubMed ID: 26329904
[TBL] [Abstract][Full Text] [Related]
2. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 in epithelial cell plasticity and tumor progression.
Cano A; Santamaría PG; Moreno-Bueno G
Future Oncol; 2012 Sep; 8(9):1095-108. PubMed ID: 23030485
[TBL] [Abstract][Full Text] [Related]
4. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
[TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1.
Kim BR; Dong SM; Seo SH; Lee JH; Lee JM; Lee SH; Rho SB
Cell Signal; 2014 Sep; 26(9):1765-73. PubMed ID: 24863880
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
7. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.
Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y
Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417
[TBL] [Abstract][Full Text] [Related]
8. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
[TBL] [Abstract][Full Text] [Related]
9. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
[TBL] [Abstract][Full Text] [Related]
10. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM
Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.
Iftikhar M; Hurtado P; Bais MV; Wigner N; Stephens DN; Gerstenfeld LC; Trackman PC
J Biol Chem; 2011 Jan; 286(2):909-18. PubMed ID: 21071451
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma.
Lin S; Zheng L; Lu Y; Xia Q; Zhou P; Liu Z
Cancer Med; 2020 Nov; 9(22):8624-8638. PubMed ID: 32970930
[TBL] [Abstract][Full Text] [Related]
13. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy.
Ye M; Song Y; Pan S; Chu M; Wang ZW; Zhu X
Pharmacol Ther; 2020 Nov; 215():107633. PubMed ID: 32693113
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
[TBL] [Abstract][Full Text] [Related]
15. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma.
Xu J; Li D; Li X; Liu Z; Li T; Jiang P; He Q; Tian F; Gao Y; Wang D; Wang S
Dig Liver Dis; 2014 Aug; 46(8):750-7. PubMed ID: 24794791
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
[TBL] [Abstract][Full Text] [Related]
17. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Barker HE; Bird D; Lang G; Erler JT
Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674
[TBL] [Abstract][Full Text] [Related]
18. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells.
Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF
Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 Inhibitors and Breast Cancer Progression.
Ferreira S; Saraiva N; Rijo P; Fernandes AS
Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
[TBL] [Abstract][Full Text] [Related]
20. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
